Affimed Therapeutics AG (DE) – Affimed successfully completes preclinical development of AFM 13

Affimed successfully completes preclinical development of AFM 13 Heidelberg, Germany; February 08 2010: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful completion of the preclinical development of its lead product AFM 13...